Welcome to our dedicated page for ASTELLAS PHARMA UNSP/ADR news (Ticker: ALPMY), a resource for investors and traders seeking the latest updates and insights on ASTELLAS PHARMA UNSP/ADR stock.
Astellas Pharma Inc. is a global pharmaceutical company with operations in over 70 countries. The company focuses on creating innovative drugs to treat diseases with high unmet medical needs by emphasizing Biology and Modality. Beyond traditional pharmaceuticals, Astellas is exploring Rx+® healthcare solutions in collaboration with cutting-edge technology partners. Astellas recently opened a state-of-the-art West Coast Innovation Center in South San Francisco, enhancing its commitment to biotech innovation.
The company is actively involved in research and development, with recent advancements in cancer therapies like zolbetuximab, a monoclonal antibody targeting gastric and gastroesophageal cancers. Astellas' collaborations with Pfizer and Merck, as well as YASKAWA Electric Corporation, demonstrate its commitment to pioneering research and creating new treatment paradigms by integrating pharmaceutical and robotics technologies.
Rhea-AI Summary
Astellas Pharma, BioLabs Global, and Mitsui Fudosan have agreed to enhance the life science ecosystem in Tsukuba and Kashiwa-no-ha, Japan by partnering to advance SakuLabTM-Tsukuba, an open innovation hub. Astellas will prepare experimental facilities for SakuLabTM-Tsukuba in its Tsukuba Research Center and provide networking opportunities for residents and researchers. The impact of this agreement has already been reflected in Astellas' financial forecast for the current fiscal year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
-
Rhea-AI Summary
Iveric Bio partners with Eric Stonestreet to raise awareness about geographic atrophy (GA), a form of age-related macular degeneration (AMD) that causes irreversible vision loss. GA currently affects approximately 1.5 million people in the United States. The campaign aims to raise awareness of potential signs and symptoms of GA and encourages individuals to talk to their eye care professional about how to monitor for the disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
-
Rhea-AI Summary
IZERVAY demonstrates positive 24-month results in reducing GA growth compared to sham, with consistent safety profile
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
News
Rhea-AI Summary
Astellas Venture Management and MBC BioLabs collaborate on the Astellas Future Innovator Prize, offering entrepreneurial scientists and biotech start-ups one year's access to lab facilities and research capabilities. Last year's winners were Bespoke Therapeutics and Cellinfinity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
-
News
Rhea-AI Summary
Astellas Pharma will present new insights into fezolinetant for the treatment of VMS due to menopause at the 2023 Annual Meeting of The Menopause Society. The presentations will include analyses on the efficacy and safety of fezolinetant in patients unsuitable for hormone therapy and the efficacy of fezolinetant on night-time VMS episodes. Real-world data on the prevalence and impact of VMS will also be presented.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Astellas Pharma plans to build a new facility in Ireland at a cost of €330 million to expand capacity and capabilities for aseptic drug products, accelerate development of innovative medicines, and reinforce global supply. The facility will be located in Tralee and will bring specialized roles to the region. The project aims to cut water use by half, reduce operational energy intensity by over one-third, and produce zero waste to landfill. Construction is expected to start in 2024 and be operational by 2028.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
Rhea-AI Summary
EMA validates Astellas Pharma's Type II variation for XTANDI® (enzalutamide) in the treatment of non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, potentially expanding its use in the EU market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
-
Rhea-AI Summary
FDA grants Priority Review for XTANDI in prostate cancer, decision expected in Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
-
Rhea-AI Summary
Astellas Pharma announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for avacincaptad pegol (ACP), an investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The MAA will be reviewed by the Committee for Medicinal Products for Human Use (CHMP) under the centralized licensing procedure for all 27 member states of the European Union (EU). GA is a form of AMD that can cause irreversible vision loss. The acceptance of the EU MAA does not impact the financial forecasts for the current fiscal year ending March 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
Rhea-AI Summary
Astellas Pharma Inc. plans to open a new life sciences facility in Cambridge, Mass. The facility will occupy two floors and house laboratory and office areas. Astellas expects a few hundred Boston-based employees to operate out of the new building. The company aims to enhance innovation and collaboration in the biopharma ecosystem.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
FAQ
What is the current stock price of ASTELLAS PHARMA UNSP/ADR (ALPMY)?
The current stock price of ASTELLAS PHARMA UNSP/ADR (ALPMY) is $9.65 as of December 24, 2024.
What is the market cap of ASTELLAS PHARMA UNSP/ADR (ALPMY)?
The market cap of ASTELLAS PHARMA UNSP/ADR (ALPMY) is approximately 18.8B.
What is Astellas Pharma Inc. known for?
Astellas Pharma Inc. is recognized as a leading global pharmaceutical company operating in over 70 countries, focusing on developing innovative drugs for diseases with high unmet medical needs.
What recent achievements has Astellas Pharma Inc. made?
Astellas recently inaugurated a modern West Coast Innovation Center in South San Francisco, enhancing its presence in the biotech ecosystem.
What is zolbetuximab, and why is it significant?
Zolbetuximab is an investigational monoclonal antibody aimed at treating gastric and gastroesophageal cancers and is a testament to Astellas' commitment to pioneering cancer therapies.
How does Astellas collaborate with other companies like Pfizer, Merck, and YASKAWA Electric Corporation?
Astellas collaborates with Pfizer, Merck, and YASKAWA Electric Corporation to advance research and development in innovative treatments through partnerships that integrate pharmaceutical and robotics technologies.
What is Astellas Pharma Inc.'s focus beyond traditional pharmaceuticals?
Astellas is exploring Rx+® healthcare solutions with cutting-edge technology partners, aiming to create innovative treatment approaches beyond traditional pharmaceuticals.
ASTELLAS PHARMA UNSP/ADR